Author

J. Tardif

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Colchicine for cardiovascular secondary prevention: evidence from recent trials and meta-analyses.

PURPOSE OF REVIEW Residual inflammatory risk remains an important driver of recurrent vascular events despite contemporary lipid-lowering and antithrombotic therapies. Low-dose colchicine is the first widely available anti-inflammatory therapy to be incorporated into contemporary guidelines for secondary prevention in...

V. Muroke, Michelle Samuel, R. Pierre et al. · Current Opinion in Cardiolog... · 0 citations

Open access Sep 2026

Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT.

BACKGROUND Although repeated testing of lipoprotein(a) [Lp(a)] is generally not recommended because of the genetically determined nature of concentrations, reports of significant intraindividual variability in serial assessments have challenged the single lifetime measurement framework. OBJECTIVE To determine sources...

M. Szarek, Deepak L. Bhatt, Michael Miller et al. · Journal of Clinical Lipidolo... · 0 citations

Open access Aug 2026

Lipid Profiles in Liver Steatosis and Liver Fibrosis in Patients with Type 2 Diabetes and Coronary Artery Disease

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2DM) have been associated with dyslipidemia. This study aimed to investigate the association between lipid values and markers of hepatic steatosis and fibrosis in patients with T2DM. Methods: This is a post hoc analysis o...

Laura A M Konings, Weiwei Xu, Vivian D. de Jong et al. · Diabetology · 0 citations